미국의 안드로겐성탈모증 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 판매채널별, 성별, 최종 용도별, 부문 예측(2025-2030년)

U.S. Androgenetic Alopecia Market Trends:

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceuticals
• Devices
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Homecare Settings
• Dermatology Clinics
• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Prescriptions
• OTC
• Gender Outlook (Revenue, USD Million, 2018 - 2030)
• Male
• Female

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Sales Channel
  • 1.2.4. Gender
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Sales Channel Outlook
  • 2.2.4. Gender Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Androgenetic Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis

Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis

• 4.1. Treatment Segment Dashboard
• 4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
• 4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Devices
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
• 5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Homecare Settings
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Dermatology Clinics
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis

• 6.1. Sales Channel Segment Dashboard
• 6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
• 6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 6.4. Prescriptions
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
• 6.5. OTC
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis

• 7.1. Male
  • 7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.2. Female
  • 7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Johnson & Johnson Services, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cipla
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Sun Pharmaceutical Industries Ltd.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Dr. Reddy's Laboratories Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Aurobindo Pharma Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Hairmax International LLC
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Curallux, LLC
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Apira Science, Inc. (iGROW Laser)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Theradome Inc.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives